AU Patent

AU2024240722A1 — Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2025-09-18 · 1y expired

What this patent protects

The present invention relates to methods for the treatment of a spinal deformity, such as thoracolumbar deformity in a subject in need of said treatment, said method comprising the step of administering a therapeutically effective amount of an inhibitor of FGFR3 signaling, or an …

USPTO Abstract

The present invention relates to methods for the treatment of a spinal deformity, such as thoracolumbar deformity in a subject in need of said treatment, said method comprising the step of administering a therapeutically effective amount of an inhibitor of FGFR3 signaling, or an NPR-B agonist and/or an NPR-C agonist to said subject.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024240722A1
Jurisdiction
AU
Classification
Expires
2025-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Endocrinology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.